Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel Antibody against Brain Tumors

22.06.2016

Scientists of Helmholtz Zentrum München and the Munich University Hospital (LMU) are developing a novel antibody to treat brain tumors. Now, with funding amounting to EUR 3.5 million approved by the Federal Ministry of Education and Research (BMBF) and the Helmholtz Validation Fund, the molecule shall undergo the first phase of clinical testing.

Glioblastoma is a very aggressive type of brain tumor. As a rule the cancer tissue is surgically removed as far as possible and the patient receives radiotherapy and/or chemotherapy. Nevertheless, due to the remaining cancer cells in the brain, the average survival time after diagnosis is only a few months.


Prof. Dr. Reinhard Zeidler, Source: Helmholtz Zentrum München / Sanni Fackler

A team of scientists led by Prof. Dr. Reinhard Zeidler, research group leader in the Research Unit Gene Vectors at Helmholtz Zentrum München and the Department of Otolaryngology of the Munich University Hospital (LMU) seeks to improve the treatment by means of a novel antibody.

Deadly delivery for tumor cells

The molecule named 6A10 specifically binds to the enzyme carbonic anhydrase XII, which is only found on cancer cells but not on healthy brain cells. It thus has two effects: first, it directly inhibits the enzyme, which is of great importance for the fast-growing tumor cells.

Second, the antibody is conjugated with lutetium-177, an isotope that is lethal for the tumor cells. The heavy metal is a beta-ray emitter and damages the cells in its immediate surroundings. Via the antibody, it reaches the remaining tumor cells directly.

Action at the tumor site

To deliver the antibody as highly concentrated as possible and as close as possible to the tumor site, the scientists plan to inject it directly at the site of the removed tumor tissue. By doing so, Zeidler and his partners Professor Hans-Jürgen Reulen, Professor emeritus of Neurosurgery at Munich University Hospital, and Dr. Franz-Josef Gildehaus from the Department of Nuclear Medicine at Munich University Hospital hope to delay or even prevent the recurrence of the disease.

“Together we have established a competent network of molecular biologists, neurosurgeons, nuclear medicine specialists, radiation physicist and radiopharmacists,” said project leader Zeidler. Both, the Department of Neurosurgery (director: Professor Tonn) and the Department of Nuclear Medicine (director: Professor Bartenstein) will play an important role in the planned clinical trials.

In the first phase, Zeidler and his colleagues want to lay the foundation for the clinical testing: “First, this involves proper production of the antibody in compliance with the mandatory law on drugs for human use.” This will be followed by the first tests on patients. As is usual in this phase, the scientists expect the initial study to have 12-15 participants who will receive the active agent.

“Our hope is that in the long term we can develop a new treatment option for glioblastoma patients” said Zeidler, looking ahead at the future. In addition to the hope of developing a successful treatment for brain tumors, Zeidler and his colleagues have their sights on other types of tumors. Since the target molecule carbonic anhydrase XII is also overexpressed in other cancer cells, it is conceivable that the molecule could be used against other forms of tumors such as lung cancer, according to the scientists.
„We hope that our project will serve as a good example that, also in an academic context, funding can help to bring scientific results from bench to bedside,” said project leader Zeidler.

Further information

Background:
The funding provided by the BMBF takes place within the framework of the VIP+ funding program for the “validation of the technological and societal innovation potential of academic research”. Its objective is to support scientists of all disciplines in taking the first step from the world of research towards economic value creation or social application.

The Helmholtz Validation Fund (HVF) is a funding instrument of the Hermann von Helmholtz Association of German Research Centres and is financed by funds from the Helmholtz President’s Initiative and Networking Fund. It aims to bridge the gaps between scientific findings and their commercial applications, between public research and private investment. In creating the Validation Fund, the Helmholtz Association seeks to minimize gaps in financing and to ease the transition from idea to application.

The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www.helmholtz-muenchen.de/en

The Research Unit Gene Vectors studies EBV's molecular functions to understand how the virus contributes to different types of disease. The scientists analyse the immune system of virus carriers to find out how EBV and other herpes viruses are kept in check, and why immune control has failed in patients with disease. They also investigate the origins of cancers of the immune system - lymphoma and leukaemia – and develop new antibodies for therapies and diagnostics. Their ultimate goal is to develop new drugs, vaccines and cell-based therapies in order to efficiently treat or – preferentially – prevent infectious diseases and cancer. http://www.helmholtz-muenchen.de/en/agv

Munich University Hospital (LMU) treats around 500,000 outpatients, inpatients and semi-residential patients each year at its Großhadern and City Centre Campuses. Just over 2,000 beds are available to its 28 specialist clinics, twelve institutes and seven departments, and its 47 interdisciplinary centres. Of a total of 9,500 employees, around 1,600 are doctors and 3,200 are nursing staff. Munich University Hospital has been a public-law institution since 2006. Together with the Medical Faculty of Ludwig Maximilians University, Munich University Hospital is involved in four special research areas of the German Research Foundation (SFB 684, 914, 1054, 1123), three Transregios (TRR 127, 128, 152) belonging to Clinical Research Group 809, and two Graduate Colleges belonging to the German Research Foundation (GK 1091, 1202). This is in addition to the Center for Integrated Protein Sciences (CIPSM), Munich Center of Advanced Photonics (MAP), Nanosystems Initiative Munich (NIM) and Munich Cluster for Systems Neurology (SyNergy) – all institutes of excellence – and the Graduate School of Systemic Neurosciences (GSN-LMU), the Graduate School of Quantitative Biosciences Munich (QBM) and the Graduate School Life Science Munich (LSM). http://www.klinikum.uni-muenchen.de

Contact for the media:
Department of Communication, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 2238 - Fax: +49 89 3187 3324 - E-mail: presse@helmholtz-muenchen.de

Scientific Contact at Helmholtz Zentrum München:
Prof. Dr. Reinhard Zeidler, Helmholtz Zentrum München - German Research Center for Environmental Health, Research Unit Gene Vectors, Research Group Prevention and Immunomodulation, Marchioninistraße 25, 81377 München - Tel. +49 89 3187 1401, E-mail: zeidler@helmholtz-muenchen.de

Weitere Informationen:

http://www.helmholtz-muenchen.de/en/news/latest-news/press-information-news/article/35075/index.html

Sonja Opitz | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

Further reports about: Antibody BRAIN Environmental Health Helmholtz cancer cells tumor cells tumors

More articles from Life Sciences:

nachricht Study shines light on brain cells that coordinate movement
26.06.2017 | University of Washington Health Sciences/UW Medicine

nachricht New insight into a central biological dogma on ion transport
26.06.2017 | Aarhus University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Study shines light on brain cells that coordinate movement

26.06.2017 | Life Sciences

Smooth propagation of spin waves using gold

26.06.2017 | Physics and Astronomy

Switchable DNA mini-machines store information

26.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>